G astrointestinal bleeding that is severe enough to be termed "clinically significant" is associated with increased mortality and longer ICU length of stay (1) . However, recent data indicate that the incidence of clinically significant stress-related gastrointestinal bleeding has been decreasing over time (2) (3) (4) , which may reflect changes in clinical practice, such as the earlier initiation of enteral feeding that protects against stress-related mucosal abnormalities via buffering gastric pH or increasing mesenteric blood flow (5, 6) .
Trials comparing histamine receptor antagonists with placebo have reported that some form of "stress ulcer prophylaxis" reduces the incidence of gastrointestinal bleeding (7) (8) (9) . Based on these historical data, recently published guidelines, sponsored by prominent national and international organizations, including the Society for Critical Care Medicine, strongly recommend prophylactic administration of acid-suppressive drugs for ventilated patients (10, 11) . Consequently, the use of acid-suppressive drugs has become widespread, with the majority of clinicians preferring to give proton pump inhibitors for this purpose (4, 12) .
It is therefore somewhat surprising that only two studies have compared the use of proton pump inhibitors with placebo to prevent gastrointestinal bleeding in critically ill patients (13, 14) . Although both studies were conducted in an open-label fashion and included only small numbers of patients (n = 147 and 30, respectively), neither reported a reduction in gastrointestinal bleeding events with prophylactic administration of proton pump inhibitors (relative risk of bleeding when prescribing a proton pump inhibitor: 1.04 [95% CIs, 0.07-16.34]) (3, 13, 14) . Accordingly, current recommendations and practice do not seem to be supported by robust evidence.
Recent observational studies have reported strong associations between the use of proton pump inhibitors and the prevalence of ventilator-associated pneumonia and Clostridium difficile infection (15, 16) . In addition, the use of proton pump inhibitors in the community is associated with an increased risk of similar infections and adverse cardiovascular events (17, 18) . Prophylactic administration of proton pump inhibitors to critically ill patients may therefore be harmful.
Because proton pump inhibitors have been inadequately evaluated in the critically ill, yet are frequently prescribed and have the potential to cause harm, we designed the Pantoprazole or Placebo for Stress Ulcer Prophylaxis (POP-UP) trial as a single-center exploratory study. Our primary objective was to evaluate whether prophylactic administration of a proton pump inhibitor is either overtly beneficial or harmful. Our secondary objectives were to 1) establish estimates of event rates with and without prophylactic pantoprazole administration of clinically significant gastrointestinal bleeding, infective ventilator-associated complication or pneumonia, Clostridium difficile infections, and hemoglobin concentrations and 2) ascertain whether the study drug could be administered promptly after commencing mechanical ventilation.
METHODS

Patients
All patients admitted to the Royal Adelaide Hospital ICU between January 28, 2014, and January 27, 2015 were evaluated. The Royal Adelaide Hospital is the major quaternary referral center in the state of South Australia for trauma, neurological injuries, and burn injuries. Patients who were anticipated to be invasively mechanically ventilated for greater than 24 hours and receive enteral nutrition within 48 hours of admission were eligible for inclusion. Exclusion criteria included are as follows: 1) use of acid-suppressive therapy prior to admission, 2) admission with gastrointestinal bleeding, 3) history of proven peptic ulcer disease, 4) administration of greater than 100 mg daily of prednisolone (or equivalent of other corticosteroid), 5) surgery on the upper gastrointestinal tract or cardiac surgery during the current hospital admission, 6) pregnancy, 7) Jehovah's witnesses, 8) patients who could not receive their first dose of study medication within 36 hours of initiation of mechanical ventilation, 9) admission for the sole purpose of providing palliative care, and 10) patients readmitted to the ICU.
The Research Ethics Committee of the Royal Adelaide Hospital approved the study protocol using delayed opt-out consent from the patient's surrogate decision maker. The rationale for this consent model was that at our institution, both treatments are perceived as standard care. The delayed opt-out consent process allows surrogate decision makers or the patient to subsequently withdraw consent, with data for these patients excluded from all analyses. The study was performed according to the National Health and Medical Research Council of Australia guidelines for the conduct of research on unconscious patients and registered with the Australian New Zealand from the clinical trial registry (http://www.anzctr.org.au, trial ID: ACTRN12613000807752).
Study Design
We conducted a prospective randomized double-blind parallel-group study. Study participants were randomly www.ccmjournal.org
October 2016 • Volume 44 • Number 10 assigned to receive pantoprazole (40 mg in 10 mL of 0.9% saline IV) or placebo (10 mL of 0.9% saline IV). The intervention was administered as a once-daily dose until the patient was no longer mechanically ventilated or for a maximum of 14 days. The intervention was also ceased at the discretion of the treating physician or if consent was withdrawn. All other treatment decisions, including interventions for any overt or clinically significant gastrointestinal bleeding, were left to the discretion of the attending physician. The hospital Department of Pharmacy performed computer-generated 1:1 ratio randomization of the allocation and prepared the blinded study drug packs.
Outcome Measures
Major outcomes of interest were clinically significant gastrointestinal bleeding, infective ventilator-associated complication or pneumonia, and Clostridium difficile infection. We deemed the use of three major outcomes necessary and acceptable because the intervention had the potential for distinct and clinically important beneficial and harmful effects (19) .
Unless specified, we collected data regarding ventilator settings (for diagnosis of infective ventilator-associated complication or pneumonia) for the duration of each participant's ICU admission or for a maximum of 7 days after ceasing the study drug. All outcomes were assessed while the investigators remained blinded to treatment allocation. Clinically significant gastrointestinal bleeding was defined as an episode of overt bleeding (hematemesis, bloody gastric aspirate, melena, or hematochezia), accompanied by at least one of the following: 1) a reduction in mean arterial blood pressure of more than or equal to 20 mm Hg within 24 hours in the absence of another cause, 2) a reduction in hemoglobin of more than or equal to 20 g/L within 24 hours, or 3) a need for endoscopy or surgery to achieve hemostasis (2). We used the Centers for Disease Control and Prevention (CDC) definitions for infective ventilator-associated complications and pneumonia (20) . Where a patient in the ICU had more than or equal to 3 bowel movements in a 24-hour period, a single stool sample was sent for Clostridium difficile toxin B DNA polymerase chain reaction testing. Patients were followed up after discharge from the ICU until hospital discharge for stool testing, as ordered at the discretion of the attending physician.
We also collected data related to minor outcomes including 1) time from initiation of mechanical ventilation to the first dose of study drug, 2) the number of doses of study drug administered per patient, 3) overt bleeding, 4) daily hemoglobin concentrations and 5) units of packed red cells transfused, 6) clinician-adjudicated ventilator-associated pneumonia (according to the criteria used previously by Davies et al (21), 7) ventilatorfree days at day 28 (22), 8) ICU and hospital length of stay, and 9) 90-day all-cause mortality.
Because coagulopathy is an established risk factor for clinically significant gastrointestinal bleeding, we categorized the presence of "hemostatic dysfunction" on enrolment (defined as international normalized ratio > 1.5; activated partial thromboplastin time > 40 s, or platelet count < 100,000/μL). We also collected data related to enteral nutrition (feed intolerance was defined as gastric residual volume > 250 mL at least once on any day) (23) and medications.
All interventions other than the study drug were left to the discretion of the treating physician.
Statistical Analysis
As our institution admits over 600 patients annually requiring mechanical ventilation for more than 24 hours, we anticipated that data from all eligible patients admitted and enrolled over a 12-month period would be sufficient for an exploratory study to identify overt benefit or harm and to provide event rate estimates for a phase III study.
Data are presented as frequencies and proportions for categorical variables and mean (sd) or median (interquartile range) for continuous variables. Rate estimates for major outcomes are also presented as exact binomial 95% CIs, except when there were no events, that is, the rate lies on a boundary, when we present the one-sided upper 97.5% interval. Patient characteristics, interventions, and primary and secondary outcomes were compared between groups using either Fisher exact or chi-square test for categorical data, unpaired Student t tests for parametric continuous variables, and Mann-Whitney U tests for nonparametric continuous variables.
Sequential daily hemoglobin and transfusion data were analyzed using a linear mixed-effects model. Mortality is presented as Kaplan-Meier failure curves, with between-group comparisons performed by log-rank test and multivariate analysis performed using Cox proportional hazards, with results reported as hazard ratios (HRs) with 95% CIs.
All analyses were conducted by intention to treat, with secondary sensitivity analysis performed per protocol. Notwithstanding the three major endpoints, we elected a priori not to adjust for multiple comparisons (19) . A two-sided p value less than 0.05 was considered statistically significant. All analyses were conducted using Stata version 14.0 (StataCorp LP, College Station, TX).
no patient other than those with overt bleeding (see Minor Outcomes section) received an open-label acid-suppressive drug.
The majority of patients received enteral nutrition during the study period, and there was no difference between the groups in terms of proportion fed, time-to-initiation, volume delivered, or feed intolerance (Table 2) .
Inotrope and corticosteroid administration was similar between the groups (Table 2 ). Approximately one third of patients had "hemostatic dysfunction" during the study, but there was no difference between groups (Table 2) . Figure 1 . During the study period, 218 patients were eligible for participation. Prior to randomization, consent was refused from the surrogate decision maker for two patients, and 216 patients received study drug. Consent for ongoing participation and retention of data was subsequently refused for two patients, so that 214 patients were included in the intention to treat analysis. Five patients ceased study drug after randomization and were withdrawn: three patients after further history was made available, indicating the use of regular proton pump inhibitor (PPI) prior to admission, one patient had cardiac surgery during admission after randomization, and one patient erroneously received open-label pantoprazole. Accordingly, 209 patients were included in the perprotocol analysis. EN = enteral nutrition, GI = gastrointestinal. (p = 0.66) or group-by-time effect (p = 0.16), with transfusion being a significant covariate (p < 0.001) (Fig. 2) . Given the apparent nonlinearity of the mean hemoglobin profiles and visual separation between groups (Fig. 2) , modeling was repeated incorporating either a linear spline at day 3 or including a polynomial term. Neither of these post hoc analysis models revealed a significant between-group or group-bytime effect. In addition, modeling for the rate of transfusion revealed no significant difference between groups. There were no differences in clinician-adjudicated ventilator-associated pneumonia (placebo: 8/108 [7 (Fig. 3) . Using a Cox proportional hazards model, the Acute Physiology and Chronic Health Evaluation III score, and age (grouped as tercile) were significant covariates (p < 0.1) with an adjusted HR for the pantoprazole group of 1.68 (0.97-2.90) (p = 0.06).
Major Outcomes
Secondary analysis of all major and minor outcomes on a per-protocol basis resulted in no change in inference.
DISCUSSION
We performed a prospective randomized double-blind parallel-group study of mechanically ventilated critically ill patients expected to receive enteral nutrition. We were able to initiate therapy promptly after commencing mechanical ventilation and analyzed data from nearly all patients who were eligible over a 12-month period and did not observe any benefit from the prophylactic administration of pantoprazole (40 mg IV once daily).
We did not observe a single episode of clinically significant gastrointestinal bleeding in either group. Although our upper CI for overall incidence of bleeding at 1.7% is considerably less than recent epidemiologic data (4), we believe that these data are complementary and indicate that clinically significant gastrointestinal bleeding in critically ill patients because of (19) 27 (25) 18 (17) 39 (37) 24 (23) 21 (20) stress-related mucosal damage now occurs infrequently (24) . We also considered it desirable to avoid occult bleeding, particularly if such gradual bleeding increases transfusion of packed red cells. However, we were unable to demonstrate any protective effect of pantoprazole on either daily hemoglobin concentration or the requirement for red cell transfusion, providing supportive evidence that gastrointestinal bleeding outcomes that are important to patients do not seem to be reduced by prophylactic pantoprazole administration. Data from our study also suggest that administration of pantoprazole does not markedly increase the risk of infective ventilator-associated pneumonia or Clostridium difficile infection, a finding that contradicts previous observational studies (15, 16) . The previous retrospective observational studies are at greater risk of bias, and accordingly, our data may represent a more precise estimate of the true effect. Nonetheless, given our relatively small sample and the infrequency of infective complications, our study may have been underpowered to detect small but clinically important harmful effects of pantoprazole.
Significance of Study Findings
Although any relatively small exploratory study should not be seen as definitive, we suggest that our data should, at the very least, encourage those clinicians who currently administer prophylactic pantoprazole to critically ill patients to reevaluate their practice and recognize that there is uncertainty as to the benefits and harm associated with the use of these agents.
It should be noted that we enrolled only mechanically ventilated critically ill patients. This cohort was targeted because they are considered to be at the greater risk of stress ulceration and gastrointestinal bleeding (2) . In addition, illness severity scores, diagnostic categories, the use of inotropes and steroids, and the prevalence of "coagulation dysfunction" in these patients suggest that the cohort we studied was indeed at least at moderate risk of stress-related mucosal damage. This has implications for current clinical practice, as observational studies indicate that many critically ill patients considered to be at low risk of gastrointestinal bleeding are administered acid-suppressive medications (4, 12, 25) , whereas data from our study suggest that stress ulcer prophylaxis with acid-suppressive medication may not be warranted even in moderate-to high-risk patients and the benefit in any low-risk cohort is therefore likely to be negligible. In addition, once commenced in the ICU, the administration of acid-suppressing drugs seems to continue inappropriately after hospital discharge (26) , and so the risks and costs associated with treatment may not be confined to the ICU period.
Strengths
Our study has robust internal validity with more rigorous methodology than that used for the two previously published trials comparing proton pump inhibitors with placebo for stress ulcer prophylaxis. To reduce selection bias, we included consecutively admitted patients who were randomized to the intervention, and to reduce performance bias, we ensured that all medical, nursing, research staff, and patients were blinded to treatment allocation throughout the study period. We also A   108 108  87  64  50  46  39  32  29  25  23  19  19  12  11   106 106  78  58  48  38  35  30  28  25  20  19  15  14 believe that prompt administration of the first dose of study drug is a substantial strength, as recent observational data indicate that at least half of all clinically significant gastrointestinal bleeding episodes occur in the first two days of ventilation (4). Accordingly, delays in commencing the intervention risk a false negative result and should be minimized during any definitive trial of stress ulcer prophylaxis. Clinically important outcomes were prospectively evaluated, so that clinically significant gastrointestinal bleeding, infective ventilator-associated conditions, and Clostridium difficile infections were quantified while blinded to reduce detection bias. Furthermore, outcomes that are at risk of subjectivity, such as ventilator-associated pneumonia, were diagnosed according to objective CDC definitions in addition to clinical criteria (27) .
LIMITATIONS
However, there are limitations to our study. Based on the findings of the meta-analysis by Marik et al (7), we only included patients who were anticipated to commence enteral feeding within 48 hours of admission. Our findings may not be generalizable to units that favor longer periods of fasting. Treating doctors only had to expect that a patient would be mechanically ventilated for greater than 24 hours for them to be eligible, which may explain why duration of ventilation was relatively short for some patients. Our results may have varied had we only included patients who were artificially ventilated for longer periods of time, but given that ventilation per se, with the first two days of ventilation being the time of the greatest risk (3), and coagulopathy are the two major risk factors for gastrointestinal bleeding (2), we believe that our cohort represented a cohort at considerable risk. It should also be recognized that we enrolled patients with a variety of presenting illnesses or injuries, which may be important as it has been hypothesized that certain pathologies, for example, presentations with a primary neurologic diagnosis may have different benefit/harm responses to stress ulcer prophylaxis (28) , and a large number of patients were excluded (n = 245) because they were receiving acid-suppressive drugs prior to ICU admission. We excluded these patients on the basis that those allocated to placebo would have the potential for rebound acid hypersecretion (29, 30) , but the unexpected prevalence of prior acid-suppressive medication use in our cohort did reduce our sample size considerably. This exclusion criterion may, in part, explain the infrequent rate of bleed we observed. We also did not conduct a traditional power calculation to determine sample size; rather, we studied a convenience sample and enrolled all eligible patients during a 12-month period. Our approach has been used by other investigators undertaking exploratory studies (31, 32) . In addition, this approach has the advantage of almost eliminating selection bias (31, 32) as in our study, we were able to analyze data from greater than 98% of patients who met the eligibility criteria during the 12-month study period. Although exploratory, our findings emphasize the pressing need to challenge current guidelines that recommend prophylactic pantoprazole be administered to mechanically ventilated critically ill patients. Given the relative infrequency with which we observed major outcomes, we believe that to detect meaningful differences, any definitive trial will need to be powered to detect relatively modest effect sizes, include larger cohorts of patients at "high risk" (such as patients with endogenous or drug-induced disturbed clotting function), precisely quantify the risks (such as Clostridium difficile) and benefits (reduction in blood transfusions) associated with the use of pantoprazole, and/or evaluate whether placebo is noninferior to pantoprazole to prevent episodes of clinically significant gastrointestinal bleeding (24, 33) . These phase III studies will be commencing soon (34, 35) . In addition, the benefit/harm profile may vary according to the class of drug, and a phase III study comparing pantoprazole and a histamine receptor antagonist is also commencing soon (36) .
CONCLUSIONS
In conclusion, we found no evidence that the prophylactic administration of pantoprazole is of benefit for or is harmful to mechanically ventilated critically ill patients who were expected to receive enteral nutrition. Our data highlight the need for larger multicenter studies to determine the safety of this approach. Figure 3 . Kaplan-Meier estimates for the probability of death (log-rank, p = 0.33).
